๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Acute Lymphoblastic Leukemia, in Relapse
Clinical trial register · China

Acute Lymphoblastic Leukemia, in Relapse Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 7 Shanghai 5 Chengdu 3 Nanchang 1 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing7 Shanghai5 Chengdu3 Nanchang1 Hangzhou1
All 5 locations
Target enrolment
to

Acute Lymphoblastic Leukemia, in Relapse trials in China

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
NCT06326008B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
Beijing GoBroad Hospital
Phase 1
48
Beijing
2026-03-15
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
NCT07070323T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2025-07-09
Not yet open
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
NCT06641024Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1
24
Shanghai
2024-11-01
Recruiting
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
NCT06213636Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell, Diffuse Large B Cell Lymphoma
Essen Biotech
Phase 1/2
75
Beijing
2024-07-10
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Recruiting
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
NCT06445803Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Rong Tao
Phase 1
48
Nanchang, Shanghai
2024-05-31
Recruiting
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
NCT06389305B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital
Not applicable
213
Beijing
2024-05-27
Recruiting
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
NCT06343090B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital
Not applicable
353
Beijing
2024-04-12
Recruiting
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
80
Beijing, Shanghai, Chengdu
2024-03-22
Recruiting
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
NCT04603872Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory
Zhejiang University
Phase EARLY_PHASE1
120
Hangzhou
2020-11-01
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/acute-lymphoblastic-leukemia-in-relapse

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Acute Lymphoblastic Leukemia, in Relapse.

How many Acute Lymphoblastic Leukemia, in Relapse trials are recruiting in China?

9 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Acute Lymphoblastic Leukemia, in Relapse), 10 studies
PhaseStudiesRecruitingShare
Phase 1/24440%
Phase 13230%
Not applicable2220%
Phase EARLY_PHASE11110%

Most active sponsors

Lead sponsors with the most studies (Acute Lymphoblastic Leukemia, in Relapse)
Lead sponsorStudiesRecruiting
Beijing GoBroad Hospital66
Chongqing Precision Biotech Co., Ltd10
Essen Biotech11
Rong Tao11
Zhejiang University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.